67 reports

  • TREATMENT GUIDELINES FOR BLADDER CANCER
  • RISK FACTORS FOR BLADDER CANCER

Bronson, S. (2018) ' FGFR Inhibition for Bladder Cancer', OncoLog, pp. ##-##.

  • Bladder Cancer
  • United States
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bladder Cancer: Executive Summary
  • RISK FACTORS FOR BLADDER CANCER

BRONSON, S. (2018) ' FGFR INHIBITION FOR BLADDER CANCER', ONCOLOG, PP. ##-##.

  • Bladder Cancer
  • Japan
  • United Kingdom
  • United States
  • Forecast

Disease Analysis: Bladder Cancer Table of Contents Executive Summary ES-## i.

  • Bladder Cancer
  • Pathology
  • United States
  • World
  • Forecast
  • Bladder cancer
  • Stages of bladder cancer

Strength: ## Low; ## High F.

  • Bladder Cancer
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Pfizer Inc.

Bladder Cancer KOL Interview – US A US KOL provides insight into the current treatment landscape for bladder cancer.

  • Bladder Cancer
  • Cancer
  • United States
  • Forecast
  • Market Size
  • EXPECTED KEY UPDATES TO THE BLADDER CANCER COMPETITIVE LANDSCAPE
  • SEVERAL KEY EVENTS WILL DRIVE CHANGES TO THE BLADDER CANCER MARKET LANDSCAPE.

Based on melanoma studies and what we know about bladder cancer, adding IDO## to PD-## does not substantially increase toxicity.

  • Bladder Cancer
  • United States
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group

Bladder Cancer: Update Bulletin ### [February 2018] This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market.

  • Bladder Cancer
  • Therapy
  • Vaccine
  • United States
  • Supply

However, NMIBCs are characterized by a high risk of recurrence, leading to a high disease burden and making bladder cancer one of the costliest malignancies to treat.

  • Bladder Cancer
  • European Union
  • Japan
  • United States
  • Market Size
  • Bladder Cancer Risk Factors
  • EU, Relative Survival of Bladder Cancer (%), Men and Women

Table ## lists two of the major risks factors for bladder cancer.

  • Bladder Cancer
  • Japan
  • United Kingdom
  • United States
  • Forecast

Bladder Cancer 2017

7595 8658 6737

Bladder Cancer 2017 ##.

  • Bladder Cancer
  • Therapy
  • United States
  • Forecast

Global Bladder Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Bladder Cancer
  • France
  • United States
  • World
  • Forecast
  • CHAPTER III BLADDER CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS

However, the sales volume of anti-bladder cancer drugs increase annually.

  • Bladder Cancer
  • China
  • Bristol-Myers Squibb China Inc Ltd
  • Sanofi-Synthelabo Inc.
  • Schering-Plough Corporation
  • Vicinium's Development in Bladder Cancer
  • Cyramza's Development in Bladder Cancer

CANCER; ##(##): ##-##.

  • Bladder Cancer
  • United States
  • Demand
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • Bladder Cancer Overview
  • Bladder Cancer Treatment Drugs Market Overview

In 1980s and 1990s, the incidence of bladder cancer per ##, ## populations was about one twentieth.

  • Bladder Cancer
  • China
  • Demand
  • Trade
  • Sanofi-Synthelabo Inc.
  • Bladder Cancer Overview
  • Bladder Cancer Treatment Drugs Market Overview

In 1980s and 1990s, the incidence of bladder cancer per ##, ## populations was about one twentieth.

  • Bladder Cancer
  • China
  • Demand
  • Market Size
  • Trade

Market Spotlight: Neuroendocrine tumors (NET), Pharma Intelligence CONTENTS ## OVERVIEW ## Latest key takeaways ## DISEASE BACKGROUND ## Risk factors ## Symptoms ## Diagnosis ## Patient segmentation ## Prognosis ## TREATMENT ## Referral patterns ## Non-muscle invasive bladder cancer

  • Bladder Cancer
  • Cancer
  • Pathology

Europe Bladder Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Bladder Cancer
  • Europe
  • France
  • Germany
  • Forecast

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • France
  • Germany
  • United States
  • Market Size
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • LATEST CLINICAL TRIALS NEWS ON NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) (SUPERFICIAL BLADDER CANCER)

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E## Countries, Clinical Trials by Phase, 2020* CLINICAL TRIALS BY PHASE IN E## COUNTRIES Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder

  • Bladder Cancer
  • Clinical Trial
  • Hospital
  • World
  • Product Initiative
  • LATEST CLINICAL TRIALS NEWS ON BLADDER CANCER
  • BLADDER CANCER THERAPEUTICS, GLOBAL, CLINICAL TRIALS IN PROGRESS BY TOP COUNTRIES, 2019*

Hoffmann-La Roche Ltd ## Nov 2018 ## Oct 2024 ## ## ## Programmed Cell Death ## Ligand ## (PD L## or B## Homolog ## or CD##) Inhibitor Programmed Cell Death ## Ligand ## (PD L## or B## Homolog ## or CD##) Intravesical Administration of

  • Bladder Cancer
  • Clinical Trial
  • Oncology
  • World
  • Product Initiative

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • France
  • Germany
  • Italy
  • Market Size
  • Major Histopathology in Bladder Cancer
  • STAGES AND HISTOPATHOLOGY OF BLADDER CANCER

Mo o r b rid ge Co u rt, ## - ## Mo o rb rid ge R o ad, M aid en h ead, SL ## ##LT, Un it ed Kin gd o m Tel : +## (##)## ## ## ## ## Black Swan An aly si s L imit e d LIST OF TABLES AND FIGURES INTRODUCTION Bladder Cancer is cancer arising in the urinary

  • Bladder Cancer
  • Cancer
  • Pathology

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Japan
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • United States
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • United Kingdom
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Italy
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • France
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Germany
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Spain
  • Market Size

Drug analysis: Cyramza

8770 10000 7800

Drug analysis: Cyramza Product Profiles Cyramza : Colorectal cancer (CRC) Cyramza : Hepatocellular carcinoma (HCC) Cyramza : Bladder cancer Cyramza : Non-small cell lung cancer (NSCLC) Cyramza : Gastric cancer LIST OF FIGURES Figure ##: Cyramza f

  • Bladder Cancer
  • European Union
  • Japan
  • United States
  • Supply